Literature DB >> 27378224

Prognostic factors, pathophysiology and novel biomarkers in Crimean-Congo hemorrhagic fever.

Esragul Akinci1, Hurrem Bodur1, Mustafa Sunbul2, Hakan Leblebicioglu3.   

Abstract

Crimean-Congo hemorrhagic fever (CCHF) is a geographically widespread tick-borne zoonosis. The clinical spectrum of the illness varies from mild infection to severe disease and death. In severe cases, hemorrhagic manifestations develop, with fatality rates of 4-20%, depending on the geographic region and quality of the health care. Although vast majority of the CCHF cases were reported from Turkey, mortality rate is lower than the other regions, which is 5% on average. Prediction of the clinical course of the disease enables appropriate management planning by the physician and prompt transportation, if needed, of the patient to a tertiary care hospital for an intensive therapy. Thus, predicting the outcome of the disease may avert potential mortality. There are numerous studies investigating the prognostic factors of CCHF in the literature. Majority of them were reported from Turkey and included investigations on clinical and biochemical parameters, severity scoring systems and some novel biomarkers. Somnolence, bleeding, thrombocytopenia, elevated liver enzymes and prolonged bleeding times are the most frequently reported prognostic factors to predict the clinical course of the disease earlier. High viral load seems to be the strongest predictor to make a clinical decision about the patient outcome. The severity scoring systems based on clinically important mortality-related parameters are especially useful for clinicians working in the field to predict the course of the disease and to decide which patient should be referred to a tertiary care hospital for intensive care. In the light of the pathophysiological characteristics of CCHF, some new biomarkers of prognosis including cytokines, soluble adhesion molecules, genetic polymorphisms and coagulopathy parameters were also investigated. However most of these tests are not available to clinicians and they were obtained mostly for research purposes. In spite of the various studies about prognostic factors, they have several inherent limitations, including large variability in the results and confusing data that are not useful for clinicians in routine practice. In this paper, the results of diverse studies of the prediction of the prognosis in CCHF based on epidemiological, clinical and laboratory findings of the disease were summarized and suggestions for future studies are provided.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Biochemistry; Crimean-Congo hemorrhagic fever; Mortality; Outcome; Prognosis; Severity scoring; Viral load

Mesh:

Substances:

Year:  2016        PMID: 27378224     DOI: 10.1016/j.antiviral.2016.06.011

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  9 in total

Review 1.  Yellow Fever Virus: Diagnostics for a Persistent Arboviral Threat.

Authors:  Jesse J Waggoner; Alejandra Rojas; Benjamin A Pinsky
Journal:  J Clin Microbiol       Date:  2018-09-25       Impact factor: 5.948

2.  Peripheral Blood Biomarkers of Disease Outcome in a Monkey Model of Rift Valley Fever Encephalitis.

Authors:  Elizabeth R Wonderlich; Amy L Caroline; Cynthia M McMillen; Aaron W Walters; Douglas S Reed; Simon M Barratt-Boyes; Amy L Hartman
Journal:  J Virol       Date:  2018-01-17       Impact factor: 5.103

3.  Association Between Severity Grading Score And Acute Phase Reactants In Patients With Crimean Congo Hemorrhagic Fever.

Authors:  Ilkay Bozkurt; Saban Esen
Journal:  Pathog Glob Health       Date:  2021-01-23       Impact factor: 2.894

Review 4.  Global research trends of World Health Organization's top eight emerging pathogens.

Authors:  Waleed M Sweileh
Journal:  Global Health       Date:  2017-02-08       Impact factor: 4.185

Review 5.  Therapeutic management of Crimean-Congo haemorrhagic fever.

Authors:  Fernando de la Calle-Prieto; Alejandro Martín-Quirós; Elena Trigo; Marta Mora-Rillo; Marta Arsuaga; Marta Díaz-Menéndez; José Ramón Arribas
Journal:  Enferm Infecc Microbiol Clin (Engl Ed)       Date:  2017-06-29

6.  Dual RNA-Seq characterization of host and pathogen gene expression in liver cells infected with Crimean-Congo Hemorrhagic Fever Virus.

Authors:  Robert A Kozak; Russell S Fraser; Mia J Biondi; Anna Majer; Sarah J Medina; Bryan D Griffin; Darwyn Kobasa; Patrick J Stapleton; Chantel Urfano; Giorgi Babuadze; Kym Antonation; Lisa Fernando; Stephanie Booth; Brandon N Lillie; Gary P Kobinger
Journal:  PLoS Negl Trop Dis       Date:  2020-04-06

Review 7.  Crimean-Congo haemorrhagic fever virus: Past, present and future insights for animal modelling and medical countermeasures.

Authors:  E J Mendoza; B Warner; D Safronetz; C Ranadheera
Journal:  Zoonoses Public Health       Date:  2018-04-20       Impact factor: 2.702

8.  Clinical and Molecular Epidemiology of Crimean-Congo Hemorrhagic Fever in Humans in Uganda, 2013-2019.

Authors:  Stephen Balinandi; Shannon Whitmer; Sophia Mulei; Luke Nyakarahuka; Alex Tumusiime; Jackson Kyondo; Jimmy Baluku; Joseph Mutyaba; Lawrence Mugisha; Maja Malmberg; Julius Lutwama; Trevor R Shoemaker; John D Klena
Journal:  Am J Trop Med Hyg       Date:  2021-10-18       Impact factor: 3.707

Review 9.  Endothelial Dysfunction, HMGB1, and Dengue: An Enigma to Solve.

Authors:  María-Angélica Calderón-Peláez; Carolina Coronel-Ruiz; Jaime E Castellanos; Myriam L Velandia-Romero
Journal:  Viruses       Date:  2022-08-12       Impact factor: 5.818

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.